6 results about "Glycoprotein binding" patented technology

The present disclosure provides antibodies and antigen-binding fragments that are capable of binding to RSV and / or MPV fusion glycoproteins and that are capable of neutralizing RSV and / or MPV infection. Also provided are polynucleotides encoding the antibodies, vectors comprising such polynucleotides, host cells capable of expressing these antibodies, related compositions, and methods of using the compositions disclosed herein, for example, to treat or prevent RSV and / or MPV infection.

The present invention describes a (first) anti-HSV antibody or antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising a sequence defined in the claims wherein the antibody or antigen-binding fragment has a sequence of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 a low dissociation rate kdis of up to 5.0 x 10 <-5 > s <-1 > and most preferably up to 2.9 x 10 <-5 > s <-1 >. In addition, the present invention also describes a combination of (A) the (first) anti-HSV antibody or antigen-binding fragment thereof; and (B) a second anti-HSV antibody or antigen-binding fragment thereof that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising the sequences defined in the claims wherein the second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Furthermore, the present invention also describes a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or antigen-binding fragment thereof, or a combination of said antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the present invention also describes an anti-HSV antibody or antigen binding fragment thereof or said combination of said antibodies for use in a method of prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, the present invention also describes a bispecific antibody that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, comprising: (A) a first binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 of the aforementioned first antibody; and (B) a second binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the aforementioned second antibody; wherein the bispecific antibody has a low dissociation rate kdis of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, at most 5.0 x 10 <-5 > s <-1 >, most preferably at most 2.9 x 10 <-5 > s <-1 >. Finally, the present invention describes a trispecific antibody comprising a third binding domain in addition to the first binding domain and the second binding domain as described for the bispecific antibody.

(A first) anti-HSV antibody or an antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims H CDR1, V H CDR3, V L CDR1, V L CDR2, and V L CDR3, and wherein the antibody or its antigen-binding fragment has a maximum dissociation rate k -4 s -1 of at most 5.0 x 10 -4 s -1 preferably at most 1.0 x 10 -5 s -1 most preferably at most 2.9 x 10 -5 s -1 is described. Further, (A) the (first) anti-HSV antibody or its antigen-binding fragment, and (B) a second anti-HSV antibody or its antigen-binding fragment that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims dis CDR1, V H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V LA combination of a second anti-HSV antibody or its antigen-binding fragment is described, comprising CDR3, wherein the second antibody has a dissociation constant Kd of up to 40 nM, preferably up to 30 nM, more preferably up to 20 nM, even more preferably up to 15 nM, up to 13 nM, and up to 10 nM. Furthermore, a pharmaceutical composition is described comprising an effective amount of the anti-HSV antibody or its antigen-binding fragment, or the combination of the antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the anti-HSV antibody or its antigen-binding fragment or the combination of the antibodies is described for use in a method for the prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, (A) V, which is the complementarity-determining region of the first antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L (B) The first binding domain containing CDR3 and (B) the complementarity determining region of the second antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L A bispecific antibody that binds to glycoprotein B(gB) of HSV-1 and / or HSV-2, comprising a second binding domain containing CDR3, with a maximum capacity of 5.0 x 10⁻¹⁴. -4 s -1 Preferably a maximum of 1.0 x 10 -4 s -1 , up to 5.0x10 -5 s -1 Most preferably a maximum of 2.9 x 10 -5 s -1 A bispecific antibody having a low dissociation rate of kdis is described. Finally, a triplicate antibody is described that includes a third binding domain in addition to the first and second binding domains described for the bispecific antibody.

The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Disclosed is a method for detecting whether a biological sample (e.g., serum, blood, plasma) contains an antibody against SARS-CoV-2 S glycoprotein, the method comprising: (i) providing a surface coated with SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody bound to the surface; wherein if a secondary antibody is detected, the biological sample contains an antibody that binds to the SARS-CoV-2 S glycoprotein.

The invention relates to a traditional Chinese medicine compound feed additive for improving animal absorption and meat quality as well as a preparation method and application of the traditional Chinese medicine compound feed additive. The traditional Chinese medicine compound feed additive is prepared from an intestinal tract conditioning group and an intestinal tract conditioning group, wherein the intestinal tract conditioning group comprises 10-20 parts of bighead atractylodes rhizome, 8-15 parts of poria cocos, 12-20 parts of medicated leaven and 10-20 parts of Chinese yam; a digestion promoting group: 10-18 parts of hawthorn and 10-18 parts of malt; the immunity enhancing group comprises 8-15 parts of astragalus membranaceus and 8-12 parts of codonopsis pilosula; and a meat quality improving group: 6-12 parts of dried orange peel and 5-10 parts of liquorice. The additive disclosed by the invention is combined with glycoprotein in gastrointestinal mucous membrane to play a role in protecting the gastrointestinal mucous membrane, rapidly repairing damaged mucous membrane, promoting mucous membrane regeneration and improving the defense capability of the gastrointestinal mucous membrane, so that the non-specific immunity and the anti-stress capability of an organism are improved; the traditional Chinese medicine composition can promote mitosis of intestinal epithelial cells and growth of intestinal villi, improve the absorption capacity of intestinal tracts to nutrient substances, accelerate gastric emptying, reduce the occurrence of excessive gastric acid caused by rumination pressure of rumen, repair damage to gastrointestinal mucosa and epithelial tissues, promote integrity of gastrointestinal structures and functions and maintain gastrointestinal flora balance.